ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-06-30 was 78.16K shares, a 36.76% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-03-31 was 480.62K shares, a 1.74% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-12-31 was 838.68K shares, a 1272.91% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-09-30 was 92.03K shares, a 42.99% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.86M shares, a 95.13% increase from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 955.74K shares, a 35.29% decline from fiscal 2020.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 1.48M shares, a 870.86% increase from fiscal 2019.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 152.13K shares, a 174.60% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2022-12-31 | 1.86M shares 10-K · filed 2023-03-01 | |
| 2021-12-31 | 955.74K shares 10-K · filed 2022-03-01 | |
| 2021-06-30 | 78.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 1.49M shares derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | 480.62K shares 10-Q · filed 2021-05-11 | 1.47M shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 838.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | 1.48M shares 10-K · filed 2021-03-16 |
| 2020-09-30 | 92.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 699.40K shares derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | 57.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 671.73K shares derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | 489.13K shares 10-Q · filed 2020-05-11 | |
| 2019-12-31 | 61.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | 152.13K shares 10-K · filed 2020-03-09 |
| 2019-09-30 | 64.36K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-12-31 | 55.40K shares 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |